Allogeneic Dual NK Cell Therapy Development focuses on creating advanced immunotherapies using engineered natural killer (NK) cells from healthy donors. This approach enhances the cells’ ability to target and eliminate cancer cells while minimizing immune rejection. It offers a promising, off-the-shelf solution for treating various cancers, providing a scalable and cost-effective alternative to personalized therapies.